参考文献/References:
[1] Cosmi L, Liotta F, Maggi E, et al. Th17 and Non-Classic Th1 cells in chronic inflammatory disorders: two sides of the same coin[J].Int Arch Allergy Immunol, 2014,164(3):171-177.
[2] Brisslert M, Bian L, Svensson MN, et al. S100A4 regulates the Src-tyrosine kinase dependent differentiation of Th17 cells in rheumatoid arthritis[J].Biochim Biophys Acta, 2014,15:925-929.
[3] Jiang W, Su J, Zhang X, et al. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease[J].Inflamm Res, 2014,47:538-547.
[4] Tao Y, Zhang X, Chopra M, et al. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis[J].J Immunol, 2014,192(12):5610-5617.
[5] Zheng XF, Sun YD, Liu XY. Correlation of expression of STAT3, VEGF and differentiation of Th17 cells in psoriasis vulgaris of Guinea pig[J].Asian Pac J Trop Med, 2014,7(4):313-316.
[6] Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the Generation of pathogenic effector TH17 and regulatory T cells[J].Nature, 2006,441(790):235-238.
[7] Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J].Immunity, 2006,24(2):179-189.
[8] Chen Z, Tato CM, Muul L, et al. Distinct regulation of interleukin-17 in human T helper lymphocytes[J].Arthritis Rheum, 2007,56(9):2936-2946.
[9] Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells[J].Nat Immunol, 2007,8(9):950-957.
[10] Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat[J].Nat Immunol, 2008,9(6):641-649
[11] Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells[J].Nature, 2008,454(722):350-352.
[12] Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages[J].Annu Rev Immunol, 2007,25:821-852.
[13] Marçal JR, Samuel RO, Fernandes D, et al. T-helper cell type 17/regulatory T-cell immunoregulatory balance in human radicular cysts and periapical granulomas[J].J Endod, 2010,36(6):995-999.
[14] El Hed A, Khaitan A, Kozhaya L, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection[J].J Infect Dis, 2010,201(6):843-854.
[15] Xing WW, Zou MJ, Liu S, et al. Hepatoprotective effects of IL-22 on fulminant hepatic failure induced by d-galactosamine and lipopolysaccharide in mice[J].Cytokine, 2011,56(2):174-179.
[16] Figueroa-Vega N,Alfonso-Pérez M, Benedicto I, et al. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis[J].J Clin Endocrinol Metab, 2010,95(2):953-962.
[17] Nanba T, Watanabe M, Inoue N, et al. Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease[J].Thyroid, 2009,19(5):495-501.
[18] Li JR, Hong FY, Zeng JY, et al. Functional interleukin-17 receptor A are present in the thyroid gland in intractable Graves disease[J].Cell Immunol, 2013,281(1):85-90.
[19] Borgogni E, Sarchielli E, Sottili M, et al. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells[J].Endocrinology, 2008,149(7):3626-3634.
[20] Dong QY, Li SJ, Gao GQ, et al. Short-term effect of radioactive Iodine therapy on CXCL-10 production in Graves' disease[J].Clin Invest Med, 2011,34(5):E262.
[21] Yan N, Yu YL, Yang J, et al. Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases[J].Autoimmunity, 2012,45(7):533-539.
[22] Kim SE, Yoon JS, Kim KH, et al. Increased serum interleukin-17 in Graves' ophthalmopathy[J].Graefes Arch Clin Exp Ophthalmol, 2012,250(10):1521-1526.
[23] Nanba T, Watanabe M, Akamizu T, et al. The -590CC genotype in the IL4 gene as a strong predictive factor for the development of hypothyroidism in Hashimoto disease[J].Clin Chem, 2008,54(3):621-623.
[24] Shi Y, Wang H, Su Z, et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto's thyroiditis[J].Scand J Immunol, 2010,72(3):250-255.
[25] Qin Q, Liu P, Liu L, et al. The increased but non-predominant expression of Th17- and Th1-specific cytokines in Hashimoto's thyroiditis but not in Graves' disease[J].Braz J Med Biol Res, 2012,45(12):1202-1208.
[26] Horie I, Abiru N, Nagayama Y, et al. T helper type 17 immune response plays an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese diabetic-H2h4 mice[J].Endocrinology, 2009,150(11):5135-5142.
[27] Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgamma function[J].Nature, 2008,453(7192):236-240.
相似文献/References:
[1]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(05):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[2]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[3]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[4]黄慧 胡欣 徐一娇 刘超.利妥昔单克隆抗体治疗Graves病的作用机制[J].国际内分泌代谢杂志,2018,38(02):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
Huang Hui,Hu Xin,Xu Yijiao,et al.Mechanism of rituximab in the treatment of Graves' disease[J].International Journal of Endocrinology and Metabolism,2018,38(05):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
[5]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(05):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
[6]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(05):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[7]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(05):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
[8]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(05):256.[doi:10.3760/cma.j.cn121383-20210420-04055]